RJA
FOMX

Raymond James & Associates’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Raymond James & Associates’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-37,500
Closed -$4K – 3471
2017
Q1 		$4K Buy
37,500
+2,000
+6% +$19.2K ﹤0.01% 3269
2016
Q4 		$82K Sell
35,500
-1,200
-3% -$11.3K ﹤0.01% 3056
2016
Q3 		$73K Buy
+36,700
New +$307K ﹤0.01% 3046

Raymond James & Associates's FOMX Position: Q1 2020 in Review

Raymond James & Associates sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 27,800 shares — an estimated $93K sold.

Raymond James & Associates first reported a position in FOMX in Q3 2016 and held it in 14 quarters. The position peaked at $455K in Q4 2016. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.

  • Raymond James & Associates reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
  • Raymond James & Associates sold 27,800 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $93K.
  • Raymond James & Associates first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q3 2016 and held it in 14 quarters.
  • Raymond James & Associates's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $455K in Q4 2016.
  • 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.

Based on Raymond James & Associates's 13F filing for Q1 2020, filed 21 Apr 2020.